ACHOUR, Miloud,FAIRHURST, Robin Alec,GRANDEURY, Arnaud,HATAKEYAMA, Shinji,KOZICZAK-HOLBRO, Magdalena,TUFILLI, Nicola,ULLRICH, Thomas
申请号：
ES14708700
公开号：
ES2637802T3
申请日:
2014.02.26
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
A pharmaceutical composition in a solid oral dosage form, which comprises 0.01 to 15% (weight / weight) of the (R) -7- (2- (1- (4-butoxy-phenyl) -2-methyl- propan-2-yl-amino) -1-hydroxy-ethyl) -5-hydroxy-benzo- [d] -thiazol-2 (3H) -one and one or more pharmaceutically acceptable excipients, wherein the (R) -7 - (2- (1- (4-Butoxy-phenyl) -2-methyl-propan-2-yl-amino) -1-hydroxy-ethyl) -5-hydroxy-benzo- [d] -thiazol-2 (3H ) -one is in an acetate salt form.Una composición farmacéutica en una forma de dosificación oral sólida, la cual comprende del 0.01 al 15 % (peso/peso) de la (R)-7-(2-(1-(4-butoxi-fenil)-2-metil-propan-2-il-amino)-1-hidroxi-etil)-5-hidroxi-benzo-[d]-tiazol-2(3H)- ona y uno o más excipientes farmacéuticamente aceptables, en donde la (R)-7-(2-(1-(4-butoxi-fenil)-2-metil-propan- 2-il-amino)-1-hidroxi-etil)-5-hidroxi-benzo-[d]-tiazol-2(3H)-ona está en una forma de sal de acetato.
